Braidwell LP Invests $29.43 Million in BioNTech SE (NASDAQ:BNTX)

Braidwell LP acquired a new position in shares of BioNTech SE (NASDAQ:BNTX) during the third quarter, Holdings Channel reports. The institutional investor acquired 247,750 shares of the company’s stock, valued at approximately $29,425,000.

A number of other large investors have also modified their holdings of the stock. CANADA LIFE ASSURANCE Co increased its holdings in BioNTech by 79.6% in the first quarter. CANADA LIFE ASSURANCE Co now owns 3,426 shares of the company’s stock valued at $316,000 after buying an additional 1,518 shares during the last quarter. Tidal Investments LLC purchased a new position in BioNTech in the first quarter valued at $703,000. EverSource Wealth Advisors LLC increased its holdings in BioNTech by 106.3% in the first quarter. EverSource Wealth Advisors LLC now owns 489 shares of the company’s stock valued at $43,000 after buying an additional 252 shares during the last quarter. GAMMA Investing LLC increased its holdings in BioNTech by 86.9% in the second quarter. GAMMA Investing LLC now owns 512 shares of the company’s stock valued at $41,000 after buying an additional 238 shares during the last quarter. Finally, Granite Bay Wealth Management LLC purchased a new position in BioNTech in the second quarter valued at $1,483,000. Hedge funds and other institutional investors own 15.52% of the company’s stock.

BioNTech Stock Up 1.8 %

NASDAQ BNTX opened at $120.72 on Friday. BioNTech SE has a 52-week low of $76.53 and a 52-week high of $131.49. The firm has a 50-day moving average price of $113.52 and a 200 day moving average price of $98.35. The company has a debt-to-equity ratio of 0.01, a current ratio of 7.33 and a quick ratio of 7.21.

BioNTech (NASDAQ:BNTX) last posted its quarterly earnings results on Monday, November 4th. The company reported $0.81 earnings per share (EPS) for the quarter, topping the consensus estimate of ($1.26) by $2.07. BioNTech had a negative net margin of 15.16% and a negative return on equity of 2.35%. The firm had revenue of $1.24 billion during the quarter, compared to analysts’ expectations of $514.08 million. During the same period in the prior year, the company posted $0.73 earnings per share. The firm’s revenue for the quarter was up 38.9% on a year-over-year basis. On average, equities research analysts predict that BioNTech SE will post -3.68 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

Several equities analysts have issued reports on the stock. Evercore ISI upgraded shares of BioNTech from an “in-line” rating to an “outperform” rating and upped their price objective for the company from $110.00 to $125.00 in a research note on Tuesday, November 19th. JPMorgan Chase & Co. decreased their price objective on shares of BioNTech from $124.00 to $122.00 and set a “neutral” rating for the company in a research note on Tuesday. The Goldman Sachs Group upgraded shares of BioNTech from a “neutral” rating to a “buy” rating and upped their price objective for the company from $90.00 to $137.00 in a research note on Friday, November 8th. Hsbc Global Res upgraded shares of BioNTech from a “hold” rating to a “strong-buy” rating in a research note on Friday, August 2nd. Finally, Deutsche Bank Aktiengesellschaft upped their price objective on shares of BioNTech from $95.00 to $150.00 and gave the company a “buy” rating in a research note on Thursday, September 19th. Four analysts have rated the stock with a hold rating, eleven have assigned a buy rating and one has issued a strong buy rating to the stock. According to MarketBeat, the company currently has an average rating of “Moderate Buy” and an average price target of $138.67.

BioNTech Profile

BioNTech SE, a biotechnology company, develops and commercializes immunotherapies for cancer and other infectious diseases. The company is developing FixVac product candidates, including BNT111, which is in Phase II clinical trial for advance melanoma; BNT112 that is in Phase I/IIa clinical trial for prostate cancer; BNT113, which is in Phase II clinical trial to treat HPV 16+ head and neck cancers; BNT114 to treat triple negative breast cancer; BNT115, which is in Phase I clinical trial in ovarian cancer; and BNT116, which is in Phase I clinical trial for non-small cell lung cancer.